{
    "nct_id": "NCT03322566",
    "official_title": "A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of stage IV NSCLC without epidermal growth factor receptor (EGFR)-sensitizing mutation, ROS1 and/or anaplastic lymphoma kinase (ALK) translocation\n* Measurable disease based on RECIST 1.1\n* Life expectancy of at least 3 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function per protocol-defined criteria.\n* Provide tumor tissue sample.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known untreated central nervous system metastases and/or carcinomatous meningitis\n* History of (non-infectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.\n* Symptomatic ascites or pleural effusion.\n* Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.\n* Active autoimmune disease that has required systemic treatment in past 2 years.\n* Has had an allogeneic tissue/solid organ transplant.\n* Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority.\n* Has known history of or is positive for active Hepatitis B (HBsAg reactive) or has active Hepatitis C (HCV RNA). Note: Testing must be performed to determine eligibility.\n* History or presence of an abnormal electrocardiogram (ECG) that, in the Investigator's opinion, is clinically meaningful.\n* Use of protocol-defined prior/concomitant therapy.",
    "miscellaneous_criteria": ""
}